What changes after one month of tesamorelin?

The most defensible early change is a lab signal, not a visible waist change. A small study of 13 healthy men found that IGF-1 rose after two weeks, but it did not measure fat loss. The large trials assessed their main CT-based visceral-fat result at 26 weeks, so one month is too early for an evidence-based picture comparison.

How long did tesamorelin take to change visceral fat in trials?

The pivotal trials used 26 weeks as the main checkpoint. In the pooled 806-person analysis, the treatment effect on CT-measured visceral fat was a 15.4% reduction at that point. Participants who continued treatment maintained an average 17.5% reduction from baseline at week 52. Those averages came from adults with HIV-associated lipodystrophy, not a general weight-loss population.

Are tesamorelin results different for men and women?

A dependable sex-specific timeline has not been established. Men and women entered the pivotal studies, but men made up 84% to 86% of participants, and the trials were not designed to produce separate month-by-month forecasts for each sex. The results also came from adults with HIV-associated lipodystrophy, which limits how they apply to other reasons for seeking care.

Why does Promise not show tesamorelin before-and-after pictures?

Pictures cannot show which abdominal fat compartment changed. Lighting, posture, clothing, camera angle and selective posting can alter how a waist looks, while the trials used CT scans to measure deep visceral fat separately from the layer under the skin. A consistent clinical measure and lab follow-up are more useful than two uncontrolled photographs.

What happens when tesamorelin is stopped?

The trial evidence suggests that the visceral-fat change is not durable after treatment ends. In a 12-month study, participants who continued tesamorelin maintained an average reduction, while those switched to placebo rapidly lost the initial improvement. That finding describes an on-treatment effect and is one reason duration belongs in a prescriber-led plan rather than a copied online cycle.

Does compounded tesamorelin undergo FDA review?

No. FDA-approved Egrifta formulations exist for reducing excess abdominal fat in adults with HIV and lipodystrophy, but the compounded tesamorelin offered here is not FDA-approved. A compounded preparation is a different product and does not inherit the brand's reviewed indication or trial results. A licensed provider may still prescribe it when clinically appropriate after reviewing the individual patient.

Tesamorelin Before and After: The Study Timeline

Tesamorelin before and after is better understood as a timeline than a pair of pictures. In human research, IGF-1, a blood marker of growth-hormone signaling, rose within two weeks. The main checkpoint for visceral adipose tissue—the deep fat around the organs—came at 26 weeks, not one month. The average reduction was maintained at 52 weeks among people who continued treatment, while fat returned after treatment stopped. These findings came from adults with HIV-associated lipodystrophy, an unusual redistribution of body fat. They are not a forecast for everyone else.

Why tesamorelin before and after photos fall short

Tesamorelin is a GHRH analogue, a lab-made version of the signal that tells the pituitary gland, a small gland below the brain, to release growth hormone. That signal can raise IGF-1 and affect body composition. It does not make a bathroom-scale reading or a photograph a precise measurement.

The main trials used computed tomography, or CT, to separate visceral fat from subcutaneous fat, the softer layer just under the skin. Lighting, posture, clothing, camera angle and selective posting can all change a picture without showing which fat compartment changed. This site does not publish before-and-after photos because they are not reliable evidence.

The fuller distinction between fat compartments belongs in the tesamorelin belly-fat guide.

What may change in the first month

The most defensible early signal is biochemical, meaning it appears in a lab result. In a small study of 13 healthy men, IGF-1 rose by an average of 181 micrograms per liter after 14 days. Researchers also measured stronger overnight growth-hormone pulses (Stanley et al., Journal of Clinical Endocrinology & Metabolism, 2011).

That study did not test visible fat loss, and 13 men are far too few to set a universal calendar. At one month, a change in IGF-1 may show that the pathway responded. It does not establish a smaller waist, a particular scale change or a result that can be seen in a photo.

The 26- and 52-week checkpoints

The clearest timeline comes from a pooled analysis of two phase 3 trials—large studies used to confirm benefits and risks—with 806 adults receiving antiretroviral therapy, medicines used to control HIV. At week 26, the treatment effect on CT-measured visceral fat was a 15.4% reduction. Abdominal subcutaneous fat did not change significantly. Mean IGF-1 rose by 108 ng/mL with tesamorelin and fell by 7 ng/mL with placebo, an inactive comparison treatment (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010).

Among participants who continued through week 52, visceral fat averaged 17.5% below the original baseline and waist circumference averaged 3.4 cm lower. Those are group averages. They do not supply a personal deadline or say what one person will see in the mirror. Whether tesamorelin works covers the wider evidence without turning these checkpoints into promises.

Checkpoint	What researchers measured	What it can honestly mean
2 weeks	IGF-1 and overnight growth-hormone pulses in 13 healthy men	An early lab response, not a visible result
26 weeks	CT-measured visceral fat in the phase 3 program	The main controlled body-composition result
52 weeks	Visceral fat and waist among continuing participants	Maintenance while treatment continued
After stopping	Visceral fat after participants switched to placebo	The earlier reduction was not durable off treatment

What happened after treatment stopped

A separate 404-person phase 3 study makes the last row important. Participants who had received tesamorelin for six months were assigned either to continue or switch to placebo for six more months. Those who continued averaged about an 18% visceral-fat reduction at 12 months. The initial improvement was rapidly lost after the switch to placebo (Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010).

The evidence therefore describes an on-treatment effect, not a permanent reset. It also explains why a short online “cycle” cannot be treated as an evidence-based plan.

Does adding ipamorelin change the timeline?

No clinical trial has tested tesamorelin with ipamorelin and measured this before-and-after timeline. Ipamorelin reaches the growth-hormone system through a different receptor, a structure on a cell that receives a signal. But a plausible mechanism is not an outcomes study. The 26- and 52-week figures belong to tesamorelin alone in the HIV trial population; they cannot be assigned to a compounded blend.

What the newest 2026 analysis adds

As of September 9, 2026, the day this article was written, a systematic review and meta-analysis—a study that combines results from several trials—published July 31, 2026 pooled four randomized trials, which assigned treatment by chance, with 909 participants. It found that visceral-fat area averaged 21.47 cm² less and waist circumference 1.61 cm less with tesamorelin than with placebo (Ditta et al., Journal of the International Association of Providers of AIDS Care, 2026).

The update did not widen the answer to a general population. Every included trial still involved people living with HIV and lipodystrophy, and the authors said long-term safety and durability data remain limited.

Men, women and the limits of the evidence

Men and women were enrolled, but the two main trials were about HIV-associated lipodystrophy, not ordinary age-related abdominal change. The current brand label reports that men made up 86% of one trial and 84% of the other. Neither study supplies a dependable month-by-month visual forecast for men or women outside that diagnosis.

The label also calls Egrifta WR weight-neutral and says it is not indicated for weight-loss management. A stable scale therefore does not rule out a change in deep abdominal fat, and a falling scale does not prove tesamorelin caused it.

Brand evidence and compounded care are different

Tesamorelin through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a pharmacy prepares the medication for an individual prescription. The current Egrifta WR prescribing information, revised in March 2025, covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. Its indication and study results do not automatically transfer to a compounded preparation or another population.

Regulatory status is one part of care, and a licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and doctor.

What a useful check-in tracks

A sensible follow-up separates three questions: did IGF-1 change, did the intended target change on an appropriate measure, and do the risks still fit the plan? Glucose, swelling, joint symptoms and injection-site reactions can matter alongside the intended outcome; tesamorelin side effects explains why those checks belong in the conversation.

At Promise, a licensed provider reviews every request and not everyone qualifies. If tesamorelin is prescribed, that provider sets the schedule and follow-up rather than using a photo or a copied calendar to decide whether treatment is earning its place. Anyone weighing it against a GLP-1 for fat loss can read tesamorelin vs tirzepatide for the side-by-side.